XML 34 R23.htm IDEA: XBRL DOCUMENT v3.24.1.u1

Revenue (Tables)

3 Months Ended

Mar. 31, 2024

Revenue

Schedule of Net product revenue in United States, and Company's net revenue

​

​	​	​	​	​	​	​
​	​	Three Months Ended
​	​	March 31,
(in thousands)		2024		​	2023
Products	​	​	​	​	​	​
UDENYCA	​	$	42,667	​	$	26,179
CIMERLI	​	​	28,194	​	​	6,174
YUSIMRY	​	​	3,894	​	​	—
LOQTORZI	​	​	1,988	​	​	—
Total net product revenue	​	​	76,743	​	​	32,353
Other	​		320	​		83
Total net revenue	​	$	77,063	​	$	32,436

Schedule of Gross Revenues by Significant Customer as a Percentage of Total Gross Revenues

​

Gross product revenues by significant customer as a percentage of total gross product revenues were as follows:

​	​	​	​	​	​
​	Three Months Ended
​	March 31,				​
​	2024		​	2023
McKesson Corporation	42	%	​	35	%
Cencora (previously known as AmeriSource-Bergen Corporation)	42	%	​	43	%
Cardinal Health, Inc.	14	%	​	21	%

Schedule of Activities and Ending Reserve Balances for Each Significant Category of Discounts and Allowances

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended March 31, 2024

​

Chargebacks

​

​

Other Fees,

​

​

​

​

and Discounts

​

​

​

​

Co-pay

​

​

​

​

​

for Prompt

​

​

​

​

Assistance

​

​

​

(in thousands)

​

Payment

​

Rebates

​

and Returns

​

Total

Balances at December 31, 2023

​

$

73,953

​

$

121,137

​

$

49,795

​

$

244,885

Provision related to sales made in:

​

​

​

​

​

​

​

​

​

​

​

​

Current period

​

​

223,619

​

​

56,432

​

​

42,359

​

​

322,410

Prior period - increase (decrease)

​

​

(504)

​

​

1,399

​

​

410

​

​

1,305

Payments and customer credits issued

​

(228,278)

​

​

(74,958)

​

​

(40,799)

​

​

(344,035)

Balances at March 31, 2024

​

$

68,790

​

$

104,010

​

$

51,765

​

$

224,565

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended March 31, 2023

​

Chargebacks

​

​

Other Fees,

​

​

​

​

and Discounts

​

​

​

​

Co-pay

​

​

​

​

​

for Prompt

​

​

​

​

Assistance

​

​

​

(in thousands)

​

Payment

​

Rebates

​

and Returns

​

Total

Balances at December 31, 2022

​

$

42,677

​

$

38,713

​

$

19,113

​

$

100,503

Provision related to sales made in:

​

​

​

​

​

​

​

​

​

​

​

​

Current period

​

93,906

​

​

13,000

​

​

14,603

​

​

121,509

Prior period - increase (decrease)

​

​

(738)

​

​

(701)

​

​

1,829

​

​

390

Payments and customer credits issued

​

(101,108)

​

(14,243)

​

(16,617)

​

(131,968)

Balances at March 31, 2023

​

$

34,737

​

$

36,769

​

$

18,928

​

$

90,434

X

- Definition

Schedule of product sales discounts and allowances.

+ References

No definition available.

+ Details

Name:	chrs_ScheduleOfProductSalesDiscountsAndAllowancesTableTextBlock
Namespace Prefix:	chrs_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-5

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-21

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-20

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-18

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-20

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 16
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-16

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-21

+ Details

Name:	us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration